CRVS Relative Valuation
CRVS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRVS is overvalued; if below, it's undervalued.
Historical Valuation
Corvus Pharmaceuticals Inc (CRVS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.24. The fair price of Corvus Pharmaceuticals Inc (CRVS) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：6.92
Fair
-13.17
PE
1Y
3Y
5Y
-9.45
EV/EBITDA
Corvus Pharmaceuticals Inc. (CRVS) has a current EV/EBITDA of -9.45. The 5-year average EV/EBITDA is -1.07. The thresholds are as follows: Strongly Undervalued below -6.62, Undervalued between -6.62 and -3.85, Fairly Valued between 1.71 and -3.85, Overvalued between 1.71 and 4.49, and Strongly Overvalued above 4.49. The current Forward EV/EBITDA of -9.45 falls within the Strongly Undervalued range.
-9.08
EV/EBIT
Corvus Pharmaceuticals Inc. (CRVS) has a current EV/EBIT of -9.08. The 5-year average EV/EBIT is -3.16. The thresholds are as follows: Strongly Undervalued below -10.46, Undervalued between -10.46 and -6.81, Fairly Valued between 0.48 and -6.81, Overvalued between 0.48 and 4.13, and Strongly Overvalued above 4.13. The current Forward EV/EBIT of -9.08 falls within the Undervalued range.
0.00
PS
Corvus Pharmaceuticals Inc. (CRVS) has a current PS of 0.00. The 5-year average PS is 51.06. The thresholds are as follows: Strongly Undervalued below -266.04, Undervalued between -266.04 and -107.49, Fairly Valued between 209.61 and -107.49, Overvalued between 209.61 and 368.16, and Strongly Overvalued above 368.16. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Corvus Pharmaceuticals Inc. (CRVS) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.50. The thresholds are as follows: Strongly Undervalued below -5.57, Undervalued between -5.57 and -3.54, Fairly Valued between 0.53 and -3.54, Overvalued between 0.53 and 2.56, and Strongly Overvalued above 2.56. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-11.61
P/FCF
Corvus Pharmaceuticals Inc. (CRVS) has a current P/FCF of -11.61. The 5-year average P/FCF is 212.19. The thresholds are as follows: Strongly Undervalued below -1442.29, Undervalued between -1442.29 and -615.05, Fairly Valued between 1039.43 and -615.05, Overvalued between 1039.43 and 1866.67, and Strongly Overvalued above 1866.67. The current Forward P/FCF of -11.61 falls within the Historic Trend Line -Fairly Valued range.
Corvus Pharmaceuticals Inc (CRVS) has a current Price-to-Book (P/B) ratio of 7.62. Compared to its 3-year average P/B ratio of 7.00 , the current P/B ratio is approximately 8.78% higher. Relative to its 5-year average P/B ratio of 4.60, the current P/B ratio is about 65.51% higher. Corvus Pharmaceuticals Inc (CRVS) has a Forward Free Cash Flow (FCF) yield of approximately -5.89%. Compared to its 3-year average FCF yield of -22.19%, the current FCF yield is approximately -73.44% lower. Relative to its 5-year average FCF yield of -31.29% , the current FCF yield is about -81.17% lower.
7.62
P/B
Median3y
7.00
Median5y
4.60
-5.89
FCF Yield
Median3y
-22.19
Median5y
-31.29
Competitors Valuation Multiple
The average P/S ratio for CRVS's competitors is 77.50, providing a benchmark for relative valuation. Corvus Pharmaceuticals Inc Corp (CRVS) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CRVS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CRVS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Corvus Pharmaceuticals Inc (CRVS) currently overvalued or undervalued?
Corvus Pharmaceuticals Inc (CRVS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.24. The fair price of Corvus Pharmaceuticals Inc (CRVS) is between to according to relative valuation methord.
What is Corvus Pharmaceuticals Inc (CRVS) fair value?
CRVS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Corvus Pharmaceuticals Inc (CRVS) is between to according to relative valuation methord.
How does CRVS's valuation metrics compare to the industry average?
The average P/S ratio for CRVS's competitors is 77.50, providing a benchmark for relative valuation. Corvus Pharmaceuticals Inc Corp (CRVS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Corvus Pharmaceuticals Inc (CRVS) as of Jan 08 2026?
As of Jan 08 2026, Corvus Pharmaceuticals Inc (CRVS) has a P/B ratio of 7.62. This indicates that the market values CRVS at 7.62 times its book value.
What is the current FCF Yield for Corvus Pharmaceuticals Inc (CRVS) as of Jan 08 2026?
As of Jan 08 2026, Corvus Pharmaceuticals Inc (CRVS) has a FCF Yield of -5.89%. This means that for every dollar of Corvus Pharmaceuticals Inc’s market capitalization, the company generates -5.89 cents in free cash flow.
What is the current Forward P/E ratio for Corvus Pharmaceuticals Inc (CRVS) as of Jan 08 2026?
As of Jan 08 2026, Corvus Pharmaceuticals Inc (CRVS) has a Forward P/E ratio of -13.17. This means the market is willing to pay $-13.17 for every dollar of Corvus Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Corvus Pharmaceuticals Inc (CRVS) as of Jan 08 2026?
As of Jan 08 2026, Corvus Pharmaceuticals Inc (CRVS) has a Forward P/S ratio of 0.00. This means the market is valuing CRVS at $0.00 for every dollar of expected revenue over the next 12 months.